| |
Expert Perspectives with PierFranco Conte, MD
Interview conducted by William Gradishar, MD, FACP
This independent medical education activity features an expert interview with PierFranco Conte, MD, that focuses on important data from the 45th ASCO Annual Meeting:
| |
PierFranco Conte, MD
Department of Oncology and Hematology
The University Hospital
Modena, Italy
William Gradishar, MD, FACP
Division of Hematology and Medical Oncology
Feinberg School of Medicine
Northwestern University
Chicago, Illinois
|
Abstract #1011: Dasatinib in advanced HER2/neu amplified and ER/PR-positive breast cancer: Phase II study CA180088.
Mayer E, Baurain J, Sparano J, Strauss L, Campone M, Fumoleau P, Rugo H, Awada A, Sy O, Llombart A
Abstract #1029: Randomized phase II study of weekly versus every-3-week ixabepilone plus bevacizumab (ixa/bev) versus paclitaxel plus bev (pac/bev) as first-line therapy for metastatic breast cancer.
Rugo HS, Campone M, Amadori D, Wardley A, Villa E, Conte PF, Mudenda B, McHenry B, Pivot X
Abstract #3: Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): Results of a randomized phase II trial.
O'Shaughnessy J, Osborne C, Pippen J, Yoffe M, Patt D, Monaghan G, Rocha C, Ossovkaya V, Sherman B, Bradley C
Disclaimer: The information on this site is intended for healthcare professionals based outside of the United States. You will be asked to provide your credentials before accessing the Webcast and slides. This site may contain information on products outside the approved indications where you practice.
This Webcast is available from July 2009 to July 2010.
This activity is supported by an educational grant from Bristol-Myers Squibb Company. |
|
